FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease

10.06.2023 - Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer’s disease The PDUFA action date for traditional approval ...

Related Keywords

South Korea ,Massachusetts ,United States ,New Zealand ,Canada ,Australia ,Cambridge ,Cambridgeshire ,United Kingdom ,Japan ,China ,Tokyo ,Russia ,Great Britain ,Jack Cox ,Haruo Naito ,Chuck Triano ,Christophera Viehbacher ,Libby Holman ,Eisai Inc ,Exchange Commission ,Eisai Europe Ltd ,National Institute On ,Investor Relations Department ,Twitter ,Communications Department ,Washington University School Of Medicine ,Eisai Co Ltd ,Facebook ,Youtube ,Public Relations Department ,National Institutes Of Health ,Biogen Inc ,Alzheimer Clinical Trial Consortium ,Nasdaq ,Alzheimer Network Trials Unit ,Linkedin ,United Nations Sustainable Development Goals Sdgs ,Central Nervous System Drugs Advisory Committee ,Drug Administration ,Biologics License Application ,Clinical Trials ,New England Journal ,Prescription Drug User Fee Act ,Prescribing Information ,Dose Management ,Carrier Status ,Antithrombotic Medication ,Innovative Licensing ,Access Pathway ,Biologics License Applications ,Clinical Trial Consortium ,National Institute ,National Institutes ,Tau Nexgen ,Dominantly Inherited ,Washington University ,Corporate Concept ,United Nations Sustainable Development Goals ,Private Securities Litigation Reform Act ,Biogen ,